CRISPR-Cas9-mediated exon skipping as a cardioprotective strategy in Duchenne muscular dystrophy.
作者信息
Wilton-Clark Harry, Yokota Toshifumi
机构信息
Department of Medical Genetics, University of Alberta, Edmonton, AB, Canada.
出版信息
Mol Ther Methods Clin Dev. 2023 Sep 4;30:500-501. doi: 10.1016/j.omtm.2023.08.013. eCollection 2023 Sep 14.
Abstract
摘要
相似文献
1
CRISPR-Cas9-mediated exon skipping as a cardioprotective strategy in Duchenne muscular dystrophy.
Mol Ther Methods Clin Dev. 2023 Sep 4;30:500-501. doi: 10.1016/j.omtm.2023.08.013. eCollection 2023 Sep 14.
2
Gene modification strategies using AO-mediated exon skipping and CRISPR/Cas9 as potential therapies for Duchenne muscular dystrophy patients.
Eng Biol. 2020 Dec 9;4(3):37-42. doi: 10.1049/enb.2020.0017. eCollection 2020 Dec.
3
An Overview of Recent Advances and Clinical Applications of Exon Skipping and Splice Modulation for Muscular Dystrophy and Various Genetic Diseases.
Methods Mol Biol. 2018;1828:31-55. doi: 10.1007/978-1-4939-8651-4_2.
4
Creation of DMD Muscle Cell Model Using CRISPR-Cas9 Genome Editing to Test the Efficacy of Antisense-Mediated Exon Skipping.
Methods Mol Biol. 2018;1828:165-171. doi: 10.1007/978-1-4939-8651-4_10.
5
Recent advancements in exon-skipping therapies using antisense oligonucleotides and genome editing for the treatment of various muscular dystrophies.
Expert Rev Mol Med. 2019 Oct 2;21:e5. doi: 10.1017/erm.2019.5.
6
Gene editing of Duchenne muscular dystrophy using biomineralization-based spCas9 variant nanoparticles.
Acta Biomater. 2022 Dec;154:597-607. doi: 10.1016/j.actbio.2022.10.015. Epub 2022 Oct 13.
7
A novel human muscle cell model of Duchenne muscular dystrophy created by CRISPR/Cas9 and evaluation of antisense-mediated exon skipping.
J Hum Genet. 2018 Mar;63(3):365-375. doi: 10.1038/s10038-017-0400-0. Epub 2018 Jan 16.
8
Applications of CRISPR/Cas9 for the Treatment of Duchenne Muscular Dystrophy.
J Pers Med. 2018 Nov 24;8(4):38. doi: 10.3390/jpm8040038.
9
Trans-generational epigenetic regulation associated with the amelioration of Duchenne Muscular Dystrophy.
EMBO Mol Med. 2020 Aug 7;12(8):e12063. doi: 10.15252/emmm.202012063. Epub 2020 Jun 29.
10
Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy.
Neuromuscul Disord. 2002 Oct;12 Suppl 1:S71-7. doi: 10.1016/s0960-8966(02)00086-x.
引用本文的文献
1
Muscular Dystrophies.
Adv Exp Med Biol. 2025;1478:245-284. doi: 10.1007/978-3-031-88361-3_11.
2
Challenges and Considerations of Preclinical Development for iPSC-Based Myogenic Cell Therapy.
Cells. 2024 Mar 29;13(7):596. doi: 10.3390/cells13070596.
本文引用的文献
1
Prevention of early-onset cardiomyopathy in exon 52-54 deletion mice by CRISPR-Cas9-mediated exon skipping.
Mol Ther Methods Clin Dev. 2023 Jul 17;30:246-258. doi: 10.1016/j.omtm.2023.07.004. eCollection 2023 Sep 14.
2
FDA approves first gene therapy for Duchenne muscular dystrophy, despite internal objections.
Nat Rev Drug Discov. 2023 Aug;22(8):610. doi: 10.1038/d41573-023-00103-y.
3
Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet. 2022 Mar 12;399(10329):1049-1058. doi: 10.1016/S0140-6736(22)00012-5.
4
Development of DG9 peptide-conjugated single- and multi-exon skipping therapies for the treatment of Duchenne muscular dystrophy.
Proc Natl Acad Sci U S A. 2022 Mar 1;119(9). doi: 10.1073/pnas.2112546119.
5
Duchenne muscular dystrophy.
Nat Rev Dis Primers. 2021 Feb 18;7(1):13. doi: 10.1038/s41572-021-00248-3.
6
A novel mouse model of Duchenne muscular dystrophy carrying a multi-exonic deletion exhibits progressive muscular dystrophy and early-onset cardiomyopathy.
Dis Model Mech. 2020 Sep 21;13(9):dmm045369. doi: 10.1242/dmm.045369.
7
rAAVrh74.MCK.GALGT2 Protects against Loss of Hemodynamic Function in the Aging mdx Mouse Heart.
Mol Ther. 2019 Mar 6;27(3):636-649. doi: 10.1016/j.ymthe.2019.01.005. Epub 2019 Jan 15.
8
Cardiac and skeletal muscle effects in the randomized HOPE-Duchenne trial.
Neurology. 2019 Feb 19;92(8):e866-e878. doi: 10.1212/WNL.0000000000006950. Epub 2019 Jan 23.
9
Duchenne and Becker Muscular Dystrophies: A Review of Animal Models, Clinical End Points, and Biomarker Quantification.
Toxicol Pathol. 2017 Oct;45(7):961-976. doi: 10.1177/0192623317734823. Epub 2017 Oct 3.
Zotero 插件